Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.
You may also be interested in...
A marketing approval for a seasonal allergic rhinitis vaccine from Allergy Therapeutics has moved nearer with positive top-line Phase II results that define the dose to be used in a Phase III study.
Circassia has put memories of last year's Cat-SPIRE disappointment firmly behind it with a new deal with AstraZeneca for Tudorza and Duaklir in COPD that will allow it to concentrate on boosting its respiratory franchise.
At a recent UK health-care conference, experts from across the health-care sector and investment community came together to explore alternative financing tactics to support businesses in their growth plans. UK investors were warned that if they continue to be overly cautious, they might risk losing out to their transatlantic counterparts.